Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis

Next Previous
X
Search
Trial Profile

A Phase 3 Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Ankylosing spondylitis
  • Focus Registrational; Therapeutic Use
  • Acronyms ATLAS
  • Sponsors Abbott Laboratories

    • Most Recent Events

    • 06 Nov 2019 Results estimating the cost per responder of ankylosing spondylitis treatment at 52 weeks with Secukinumab versus Adalimumab based on the Assessment of Spondyloarthritis International Society outcomes presented at the 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 08 Nov 2017 Results of a post-hoc analysis assessing the impact of time since diagnosis, age, and number of prior NSAIDs as surrogates for disease duration on clinical outcomes in ankylosing spondylitis (AS) patients from ATLAS trial treated with Adalimumab for 52 weeks, presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 17 Jun 2017 Results of post-hoc analysis assessing clinical outcomes at week 52, presented at the 18th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top